Voting Results of Cosmo's 2025 AGM

Rhea-AI Summary

Cosmo Pharmaceuticals announced successful voting results from its 2025 Annual General Meeting, with shareholders approving all items on the agenda. The meeting saw representation of 9,135,061 ordinary shares, constituting 52.07% of total outstanding shares. A key highlight was the approval of a €2.05 per share dividend, marking a 2.5% increase from the previous year. The dividend will be distributed with an ex-dividend date of June 4, 2025, and payment date of June 6, 2025. Chairman Alessandro Della Chà expressed gratitude for shareholders' trust, while CEO Giovanni Di Napoli announced an upcoming Investor Day scheduled for July 1 in Zurich to discuss ongoing and future projects.

Positive

• Approved dividend of €2.05 per share, representing a 2.5% increase from previous year
• Strong shareholder participation with 52.07% of total outstanding shares represented at AGM
• All voting items received shareholder approval, indicating strong alignment with management

Negative

• None.

Dublin, Ireland--(Newsfile Corp. - May 30, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced that its shareholders approved all voting items at today’s Ordinary Annual General Meeting. A total of 9,135,061 ordinary shares of the share capital of Cosmo were represented at this general meeting of shareholders. These shares make up 52.07% of the total outstanding ordinary shares in the share capital of Cosmo as of the record date.

Among others, the shareholders of Cosmo approved a dividend of €2.05 per share, a dividend distribution increase of 2.5% compared to the prior year. The ex-dividend date will be 4 June 2025, and payment will be made on 6 June 2025. The full voting results of the 2025 AGM and detailed dividend payment information for shareholders are available in the AGM section of the Company’s website.

Alessandro Della Chà, Chairman of Cosmo, commented: “On behalf of the entire Board, I would like to thank all our shareholders for their continued trust and their participation in this year’s Annual General Meeting. We remain committed to delivering long-term value, and we are grateful to have them on this journey with us.”

Giovanni Di Napoli, CEO of Cosmo, added: “We are now looking forward to providing our stakeholders, including financial analysts and media representatives, with further insights into our ongoing and future projects at our upcoming Investor Day on 1 July in Zurich.”

About Cosmo

Cosmo Pharmaceuticals N.V. is committed to revolutionizing healthcare and transforming people’s lives by researching and developing innovative products that tackle unfulfilled healthcare demands. As a pharmaceutical company, Cosmo is active in the areas of Healthtech/AI, dermatology, gastroenterology and contract manufacturing & development. For the commercialization and distribution of its products, Cosmo collaborates with leading partners worldwide, including Medtronic and Sun Pharma. Founded in 1997, Cosmo is headquartered in Dublin (Ireland) and has offices also in San Diego (USA), and Lainate/Rome/Catania (Italy). The Company has approximately 330 employees at the end of 2024, all dedicated to making a significant impact in the field of healthcare. For more information, please visit www.cosmopharma.com.

Upcoming Events

Jefferies Healthcare Conference, New York	June 3-5, 2025
Investor Day, Zurich	July 1, 2025
2025 Half-Year Results and Report	July 23, 2025

 

For further information, please contact:

investor.relations@cosmopharma.com

Attachments

PDF - English

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253966

FAQ

What dividend did Cosmo Pharmaceuticals (CMOPF) approve for 2025?

Cosmo Pharmaceuticals approved a dividend of €2.05 per share for 2025, representing a 2.5% increase from the previous year.

When is the ex-dividend date for Cosmo's 2025 dividend?

The ex-dividend date is June 4, 2025, with payment scheduled for June 6, 2025.

What was the shareholder participation rate at Cosmo's 2025 AGM?

The AGM had representation of 9,135,061 ordinary shares, constituting 52.07% of total outstanding shares.

When is Cosmo Pharmaceuticals' Investor Day 2025?

Cosmo's Investor Day is scheduled for July 1, 2025, in Zurich.

Were all voting items approved at Cosmo's 2025 AGM?

Yes, shareholders approved all voting items at the 2025 Annual General Meeting.